Nespacel

N/A

Report date: 2025/05/12 13:22:56

Base Information

Drug NameNespacel
Drug Alias NameAT-101
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-CD19
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsHematologic NeoplasmsLymphoma, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAbclon Inc
China Registration ClassN/A

Develop Information

Active CompaniesAbclon IncChong Kun Dang Pharmaceutical Corp
Inactive CompaniesN/A
Active IndicationsHematologic NeoplasmsLymphoma, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A